home / openregs

documents

Regulatory documents from Regulations.gov including rules, proposed rules, notices, and supporting materials.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

22 rows where docket_id = "FDA-2020-D-1136" and posted_year = 2020 sorted by posted_date descending

✎ View and edit SQL

This data as json, CSV (advanced)

Suggested facets: title, subtype, posted_date, posted_month, comment_start_date, comment_end_date, open_for_comment, posted_date (date), comment_start_date (date), comment_end_date (date), last_modified (date)

document_type 2

  • Other 17
  • Notice 5

posted_year 1

  • 2020 · 22 ✖

agency_id 1

  • FDA 22
id agency_id docket_id title document_type subtype posted_date ▲ posted_year posted_month comment_start_date comment_end_date last_modified fr_doc_num open_for_comment withdrawn object_id
FDA-2020-D-1136-0044 FDA None FDA-2020-D-1136 Review Timelines for Applicant Responses to Complete Response Letters When a Facility Assessment Is Needed During the COVID-19 Public Health Emergency Guidance for Industry Other Guidance 2020-12-23T05:00:00Z 2020 12 2020-12-23T05:00:00Z 2023-05-12T03:59:59Z 2023-05-08T19:02:22Z   0 0 09000064849bcedf
FDA-2020-D-1136-0040 FDA None FDA-2020-D-1136 Guidance Documents Related to Coronavirus Disease 2019 (COVID–19); Availability Notice Notice of Availability 2020-10-16T04:00:00Z 2020 10 2020-10-16T04:00:00Z   2021-03-05T14:37:40Z 2020-22968 0 0 0900006484912a7f
FDA-2020-D-1136-0064 FDA None FDA-2020-D-1136 Resuming Normal Drug and Biologics Manufacturing Operations During the COVID-19 Public Health Emergency Guidance for Industry - September 2020 U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research Center for Biologics Evaluation and Research Center for Other Guidance 2020-09-10T04:00:00Z 2020 9 2021-04-28T04:00:00Z 2023-05-12T03:59:59Z 2023-05-08T19:44:20Z   0 0 0900006484abaf0f
FDA-2020-D-1136-0035 FDA None FDA-2020-D-1136 Manufacturing, Supply Chain, and Drug and Biological Product Inspections During COVID-19 Public Health Emergency Questions and Answers Guidance for Industry Other Guidance 2020-08-19T04:00:00Z 2020 8 2020-08-19T04:00:00Z 2023-11-08T04:59:59Z 2023-05-24T20:08:59Z   0 0 0900006484811bad
FDA-2020-D-1136-0033 FDA None FDA-2020-D-1136 Guidance Documents Related to Coronavirus Disease 2019; Availability Notice Notice of Availability 2020-08-03T04:00:00Z 2020 8 2020-08-03T04:00:00Z   2021-03-05T14:37:26Z 2020-16852 0 0 09000064847ccc07
FDA-2020-D-1136-0024 FDA None FDA-2020-D-1136 Guidance Documents Related to Coronavirus Disease 2019 (COVID–19); Availability Notice Notice of Availability 2020-06-26T04:00:00Z 2020 6 2020-06-26T04:00:00Z   2021-03-05T14:37:11Z 2020-13829 0 0 090000648470facc
FDA-2020-D-1136-0021 FDA None FDA-2020-D-1136 Good Manufacturing Practice Considerations for Responding to COVID-19 Infection in Employees in Drug and Biological Products Manufacturing - Guidance for Industry Other Guidance 2020-06-19T04:00:00Z 2020 6 2020-06-19T04:00:00Z 2023-05-12T03:59:59Z 2023-05-08T19:50:01Z   0 0 09000064846fac55
FDA-2020-D-1136-0020 FDA None FDA-2020-D-1136 Statistical Considerations for Clinical Trials During the COVID-19 Public Health Emergency - Guidance for Industry Other Guidance 2020-06-16T04:00:00Z 2020 6 2020-06-16T04:00:00Z 2023-05-12T03:59:59Z 2023-05-09T19:04:53Z   0 0 09000064846f4ae5
FDA-2020-D-1136-0019 FDA None FDA-2020-D-1136 Temporary Policy on Prescription Drug Marketing Act Requirements for Distribution of Drug Samples During the COVID-19 Public Health Emergency - Guidance for Industry Other Guidance 2020-06-08T04:00:00Z 2020 6 2020-06-08T04:00:00Z 2023-05-12T03:59:59Z 2023-05-09T19:19:18Z   0 0 09000064846d5e86
FDA-2020-D-1136-0015 FDA None FDA-2020-D-1136 Effects of the COVID-19 Public Health Emergency on Formal Meetings and User Fee Applications - Questions and Answers Guidance for Industry Other Guidance 2020-05-26T04:00:00Z 2020 5 2020-05-27T04:00:00Z 2023-05-12T03:59:59Z 2023-05-09T19:07:05Z   0 0 09000064846b4184
FDA-2020-D-1136-0014 FDA None FDA-2020-D-1136 Guidance Documents Related to Coronavirus Disease 2019 (COVID–19); Availability Notice Notice of Availability 2020-05-26T04:00:00Z 2020 5 2020-05-26T04:00:00Z   2021-03-05T14:36:27Z 2020-11238 0 0 09000064846ac913
FDA-2020-D-1136-0013 FDA None FDA-2020-D-1136 Temporary Policy for Compounding of Certain Drugs for Hospitalized Patients by Outsourcing Facilities During the COVID-19 Public Health Emergency - List of Drugs Used for Hospitalized Patients with COVID-19 Other Background Material 2020-05-22T04:00:00Z 2020 5     2023-05-12T14:00:04Z   0 0 090000648467120c
FDA-2020-D-1136-0012 FDA None FDA-2020-D-1136 COVID-19 Public Health Emergency_ General Considerations for Pre-IND_Meeting Requests for COVID-19 Related Drugs and Biological Pr-2 Other Guidance 2020-05-13T04:00:00Z 2020 5 2020-05-13T04:00:00Z 2023-05-12T03:59:59Z 2023-05-09T19:20:08Z   0 0 09000064845e8851
FDA-2020-D-1136-0011 FDA None FDA-2020-D-1136 Temporary Policy for Compounding of Certain Drugs for Hospitalized Patients by Pharmacy Compounders not Registered as Outsourcing Facilities During the COVID-19 Public Health Emergency - Guidance for Industry Other Guidance 2020-05-08T04:00:00Z 2020 5 2020-05-08T04:00:00Z 2023-05-12T03:59:59Z 2023-05-09T19:17:11Z   0 0 0900006484591e7a
FDA-2020-D-1136-0010 FDA None FDA-2020-D-1136 Temporary Policy for Compounding of Certain Drugs for Hospitalized Patients by Outsourcing Facilities During the COVID-19 Public Health Emergency - Guidance for Industry Other Guidance 2020-05-08T04:00:00Z 2020 5 2020-05-08T04:00:00Z 2023-05-12T03:59:59Z 2024-11-12T23:19:39Z   1 0 0900006484591e78
FDA-2020-D-1136-0009 FDA None FDA-2020-D-1136 Exemption and Exclusion from Certain Requirements of the Drug Supply Chain Security Act During the COVID-19 Public Health Emergency Guidance for Industry Other Guidance 2020-04-30T04:00:00Z 2020 4 2020-04-30T04:00:00Z 2023-05-12T03:59:59Z 2023-05-09T19:20:27Z   0 0 090000648452228f
FDA-2020-D-1136-0007 FDA None FDA-2020-D-1136 Temporary Policy on Repackaging or Combining Propofol Drug Products During the COVID-19 Public Health Emergency Guidance for Industry Other Guidance 2020-04-22T04:00:00Z 2020 4 2020-04-22T04:00:00Z   2024-11-06T23:33:49Z   1 0 09000064844c296a
FDA-2020-D-1136-0006 FDA None FDA-2020-D-1136 Temporary Policy for Compounding of Certain Drugs for Hospitalized Patients by Pharmacy Compounders not Registered as Outsourcing Facilities During the COVID-19 Public Health Emergency Guidance for Industry Other Guidance 2020-04-20T04:00:00Z 2020 4 2020-04-20T04:00:00Z 2023-05-12T03:59:59Z 2023-05-09T19:16:50Z   0 0 09000064844b9a04
FDA-2020-D-1136-0004 FDA None FDA-2020-D-1136 Temporary Policy for Compounding of Certain Drugs for Hospitalized Patients by Outsourcing Facilities During the COVID-19 Public Health Emergency Guidance for Industry Other Guidance 2020-04-16T04:00:00Z 2020 4 2020-04-16T04:00:00Z 2023-05-12T03:59:59Z 2023-05-09T19:08:50Z   0 0 09000064844abbb7
FDA-2020-D-1136-0003 FDA None FDA-2020-D-1136 Temporary Policy Regarding Non-Standard PPE Practices for Sterile Compounding by Pharmacy Compounders not Registered as Outsourcing Facilities During the COVID-19 Public Health Emergency Other Guidance 2020-04-10T04:00:00Z 2020 4 2020-04-10T04:00:00Z 2023-05-12T03:59:59Z 2023-05-09T19:18:35Z   0 0 0900006484499af1
FDA-2020-D-1136-0002 FDA None FDA-2020-D-1136 Policy for the Temporary Use of Portable Cryogenic Containers Not in Compliance With 21 CFR 211.94(e)(1) For Oxygen and Nitrogen During the COVID-19 Public Health Emergency Guidance for Industry Other Guidance 2020-04-09T04:00:00Z 2020 4 2020-04-09T04:00:00Z 2023-11-08T04:59:59Z 2023-05-24T20:07:17Z   0 0 090000648449747d
FDA-2020-D-1136-0001 FDA None FDA-2020-D-1136 Process for Making Available Guidance Documents Related to Coronavirus Disease 2019 Notice Announcement 2020-03-25T04:00:00Z 2020 3 2020-03-25T04:00:00Z   2021-03-05T14:35:54Z 2020-06222 0 0 090000648446b620

Advanced export

JSON shape: default, array, newline-delimited, object

CSV options:

CREATE TABLE documents (
    id TEXT PRIMARY KEY,
    agency_id TEXT,
    docket_id TEXT REFERENCES dockets(id),
    title TEXT,
    document_type TEXT,
    subtype TEXT,
    posted_date TEXT,
    posted_year INTEGER,
    posted_month INTEGER,
    comment_start_date TEXT,
    comment_end_date TEXT,
    last_modified TEXT,
    fr_doc_num TEXT,
    open_for_comment INTEGER,
    withdrawn INTEGER,
    object_id TEXT
);
CREATE INDEX idx_docs_agency ON documents(agency_id);
CREATE INDEX idx_docs_docket ON documents(docket_id);
CREATE INDEX idx_docs_date ON documents(posted_date);
CREATE INDEX idx_docs_year ON documents(posted_year);
CREATE INDEX idx_docs_type ON documents(document_type);
CREATE INDEX idx_docs_frnum ON documents(fr_doc_num);
CREATE INDEX idx_docs_comment_end ON documents(comment_end_date) WHERE comment_end_date IS NOT NULL AND withdrawn = 0;
Powered by Datasette · Queries took 542.435ms · Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API